Manufacturing Chemist ACG
  1. Registration
  2. Survey
  3. Verification
  4. Confirmation
Registration is simple
Enter your business email and continue
Please note your information is always protected by our privacy policy and we do not share your data with any third party without your consent.

Payload cleaning and analytics: overcoming the challenges of payload cleaning and analytics in ADC manufacturing

WEBINAR DATE: 29 January 2026
TIME: 15:00 GMT / 16:00 CET / 11:00 EDT

Bringing a biologic to market—especially complex modalities like Antibody-Drug Conjugates (ADCs)—requires not only significant investment but seamless integration across development and manufacturing. In this session, Samsung Biologics will share insights on navigating the unique challenges of ADC Drug Substance manufacturing, including payload handling, flexible manufacturing set-up, and cross contamination management. The presentation will also highlight how our recent expansions in ADC capabilities are enabling faster timelines, integrated solutions, and greater manufacturing efficiency for global biopharma partners.

What you can expect:

  • Introduction
    - The evolving landscape of cancer treatment: How ADCs are reshaping oncology
    - Complexity in supply chain & project management when bringing an ADC to IND and market
     
  • Overcoming ADC Manufacturing Challenges
    - Cytotoxic payload handling to fulfill safety and adhere to quality
    - Flexible and mobile set-up for complex ADC manufacturing processes
    - Cross contamination and cleaning strategies in an ADC facility
     
  • Advancing with Samsung Biologics’ ADC Capabilities
    - End-to-end ADC services: From development to commercial-scale manufacturing
    - Integrated solutions to ensure safety, speed, and quality in ADC production

Meet the speaker:

Marc Studer, Senior Director and Head of ADC/mRNA Operations at Samsung Biologics

Marc

Marc brings extensive experience in the CDMO industry and has held roles across quality control, process development, and operations.  Prior to joining Samsung Biologics, Mr. Studer served as Associate Director at Lonza, overseeing clinical and commercial bioconjugate manufacturing and the design and scale-up of new manufacturing assets. He holds a Master’s degree in Pharmaceutical Biotechnology from Zurich University of Applied Sciences in Switzerland.

Register for the webinar today:

  • Enter your email and click "Continue" to see if your details are on our system.
  • Fill in your contact details if we do not have them.
  • Confirm it's really you by receiving our verification email.

Terms & Conditions | Privacy Policy | Contact us at info@hpcimedia.com or + 44 (0) 20717 05858

© HPCi Media Limited | Registered in England No. 6716035 | Studio 227-8, Metal Box Factory, 30 Great Guildford St, London SE1 0HS | VAT GB 939828072